Two new guidances for the use of GnRHa and aromatase inhibitors for optimising linear growth and final height

In response to an identified unmet need by BSPED members, the BSPED Growth Disorders Special Interest group (SIG) is delighted to share two new guidances for the use of GnRHa and aromatase inhibitors for optimising linear growth and final height. These have been developed to support clinicians considering using these medicines for growth management in different clinical scenarios and provide a practical, pragmatic and structured approach for their use.

The guidance can be found on the BSPED website here:

GnRHa:

“Guidance for use of gonadotropin-releasing hormone analogues (GnRHa) to optimise linear growth and final height” 

Aromatase inhibitors:

“Guidance for use of aromatase inhibitors to optimise linear growth and final height”